跳至主要内容
临床试验/NCT01618773
NCT01618773已完成不适用

Epiduo in the Long-term Treatment of Moderate to Severe Acne With or Without Concomitant Medication

Galderma Laboratorium GmbH0 个研究点目标入组 6,036 人开始时间: 2012年6月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
6,036
主要终点
Severity of acne

研究概览

简要总结

This observational study is designed to assess the long-term efficacy and safety of Epiduo (alone or in combination with other drugs) under daily clinical practice conditions in patients with moderate to severe inflammatory acne. In addition, the effect of Epiduo on quality of life and patient adherence will be assessed under marketed conditions.

详细描述

This observational study is designed to assess the long-term efficacy and safety of Epiduo under daily clinical practice conditions. The study includes patients of all ages with moderate to severe inflammatory acne, taking Epiduo alone or in combination with other drugs. In addition, the effect of Epiduo alone or in combination with other drugs on quality of life and patient adherence will be assessed under marketed conditions.

The observational study is designed as a multicentre study, covering all parts of Germany. Participating investigators are dermatologists with an adequate patient pool of acne patients. The observation time per patient will be 9 months. An interim and final examination with subsequent documentation are designated to be performed about 3 and 9 months after the start of treatment, respectively.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • The patient has been diagnosed with moderate to severe inflammatory acne (Leeds Grade 4-12)
  • Topical therapy of acne with Epiduo is indicated, the decision about treating the patient with Epiduo has been made independently from this study

排除标准

  • Use of Epiduo within 3 months prior to inclusion
  • Pregnancy or breastfeeding
  • Acne inversa
  • Acne with preferential manifestation of microcysts, macrocysts and macrocomedones
  • Hypersensitivity to the drug or any of its ingredients
  • If applicable, other restrictions outlined in the SPC of Epiduo

结局指标

主要结局

Severity of acne

时间窗: at baseline and after 3 and 9 months treatment

Efficacy is assessed by change in severity of acne according to the Leeds revised grading system

次要结局

  • Quality of Life(at baseline and after 3 and 9 months of treatment)
  • Treatment adherence(after 3 and 9 months of treatment)
  • Local Skin Irritations(over 9 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Long-term Study of Epiduo in Patients With Moderate... | 临床试验